Remodeling of the extracellular matrix is necessary for tumor cells to invade and metastasize. Matrix metalloproteinases (MMP) are widely accepted as the proteinases responsible for ECM remodeling. Although MMP are important for wound repair, growth and development, work from many laboratories has implicated increased MMP activity in the process of tumor cell invasion and metastasis. MMP activity is controlled by a family of protein inhibitors called Tissue Inhibitors of Metalloproteinases (TIMP). TIMPs have been shown to decrease the invasive potential of tumor cells in vitro and in vivo suggesting that the invasive potential of tumor cells may be modulated by inhibition of metalloproteinases. Therefore, understanding the mechanisms of metalloproteinase inhibition may lead to new therapies to fight tumor cell invasion and metastasis. In addition to the known TIMPs, a metalloproteinase inhibitor of molecular weight 16,500 has been observed in medium conditioned by some human brain tumors and transformed epithelial cells. Recently, this inhibitor was purified from brain tumor cells and identified as the C-terminus of a protein originally identified as procollagen C-terminal proteinase enhancer (PCPE). This inhibitor activity has been designated CT-PCPE. Inhibitor activity has only been associated with the C-terminus of PCPE. Intact PCPE, a 55 kDa glycoprotein, is not a metalloproteinase inhibitor. Intact PCPE and N-terminal 34 kDa and 36 kDa fragments enhance the activity of procollagen C-terminal proteinase (PCP). CT-PCPE inhibits MMP-2 and MMP-7 in solution with an IC-5O value of 560 nM and 50 nM respectively. However, it is unknown if MMPs are the only metalloproteinase targets for CT-PCPE inhibition. Experiments are proposed to identify the structural components of CT-PCPE responsible for metalloproteinase inhibition and to determine which metalloproteinases constitute physiological targets. In addition, experiments are proposed to identify proteinases responsible for the generation of CT-PCPE inhibitory activity and to determine if both enhancer and inhibitor activities can be released from PCPE by the same proteolytic event. These experiments will provide information regarding the control of metalloproteinase activity in tumor biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA088858-03
Application #
6633871
Study Section
Pathobiochemistry Study Section (PBC)
Program Officer
Ault, Grace S
Project Start
2001-07-01
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$266,299
Indirect Cost
Name
Lawrence Berkeley National Laboratory
Department
Type
Organized Research Units
DUNS #
078576738
City
Berkeley
State
CA
Country
United States
Zip Code
94720
Beliveau, Alain; Mott, Joni D; Lo, Alvin et al. (2010) Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev 24:2800-11
Morimoto, Hisanori; Wada, Jun; Font, Bernard et al. (2008) Procollagen C-proteinase enhancer-1 (PCPE-1) interacts with beta2-microglobulin (beta2-m) and may help initiate beta2-m amyloid fibril formation in connective tissues. Matrix Biol 27:211-9
Rizki, Aylin; Weaver, Valerie M; Lee, Sun-Young et al. (2008) A human breast cell model of preinvasive to invasive transition. Cancer Res 68:1378-87
Williamson, Richard A; Panagiotidou, Parthena; Mott, Joni D et al. (2008) Dynamic characterisation of the netrin-like domain of human type 1 procollagen C-proteinase enhancer and comparison to the N-terminal domain of tissue inhibitor of metalloproteinases (TIMP). Mol Biosyst 4:417-25
Rizki, Aylin; Mott, Joni D; Bissell, Mina J (2007) Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 67:11106-10
Mott, Joni D; Werb, Zena (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558-64